Breast cancer‐related lymphedema: A comprehensive analysis of risk factors
Charalampos Siotos,Sydney H. Arnold,Michelle Seu,Lilia Lunt,Jennifer Ferraro,Daniel Najafali,George Damoulakis,Joshua Vorstenbosch,Babak J. Mehrara,Anuja K. Antony,Deana S. Shenaq,George Kokosis
DOI: https://doi.org/10.1002/jso.27841
2024-08-29
Journal of Surgical Oncology
Abstract:Background Breast cancer‐related lymphedema is a devastating condition that negatively affects the quality of life of breast cancer survivors. We sought to identify risk factors that predicted the timing and development of lymphedema. Methods Women with breast cancer that underwent sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND) at our institution between 2007 and 2022 were identified and sociodemographic and clinical information was extracted. We used logistic regression analysis to identify risk factors for lymphedema and performed cox‐regression analysis to predict the timing of lymphedema presentation after surgery. Results We identified 1,223 patients, of which 161 (13.2%) developed lymphedema within 1.8 (mean, SD = 2.5) years postoperatively. Patients with SLNB had significantly lower odds for lymphedema development (vs. ALND, OR = 0.29 [0.14–0.57]). Patients between 40 and 49 years of age, and 50‐59 (vs. <40 years, OR = 2.14 [1.00–4.60]; OR = 2.42, [1.13–5.16] respectively), African American patients (vs. Caucasian, OR = 1.86 [1.12–3.09]), patients with stage II, III, and IV disease (vs. stage 0, OR = 3.75 [1.36–10.33]; OR = 6.62 [2.14–20.51]; OR = 9.36 [2.94–29.81]), and patients with Medicaid (vs. private insurance, OR = 3.56 [1.73–7.28]) had higher rates of lymphedema. Cox‐regression analysis showed that African American (HR = 1.71 [1.08–2.70]), higher BMI (HR = 1.03 [1.00–1.06]), higher stage (stage II, HR = 2.22 [1.05–7.09]; stage III, HR = 5.26 [1.86–14.88]; stage IV, HR = 6.13 [2.12–17.75]), and Medicaid patients (HR = 2.15 [1.12–3.80]) had higher hazards for lymphedema. Patients with SLNB had lower hazards for lymphedema (HR = 0.43 [0.87–2.11]). Conclusion Lymphedema has identifiable risk factors that can reliably be used to predict the chances of lymphedema development and enable clinicians to educate patients better and formulate treatment plans accordingly. Level of Evidence III (Retrospective study).
oncology,surgery